1800-272-662
Shopping Cart 0
countryflagAU
Login

Vita Life Sciences Ltd

Healthcare AU VLS

2.48AUD
-0.02(0.80%)

Last update at 2026-03-13T05:10:00Z

Day Range

2.482.49
LowHigh

52 Week Range

1.672.84
LowHigh

Fundamentals

  • Previous Close 2.50
  • Market Cap136.30M
  • Volume10950
  • P/E Ratio13.89
  • Dividend Yield5.62%
  • EBITDA14.52M
  • Revenue TTM93.27M
  • Revenue Per Share TTM1.67
  • Gross Profit TTM 57.04M
  • Diluted EPS TTM0.18

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 14.43M 12.64M 12.45M 10.74M 11.20M
Minority interest - 0.00500M 0.00200M -0.25700M 0.04M
Net income 10.44M 8.78M 9.08M 7.08M 8.29M
Selling general administrative 41.40M 19.26M 18.06M 16.69M 14.65M
Selling and marketing expenses - 13.89M 11.37M 10.42M 7.57M
Gross profit 56.03M 47.24M 42.60M 39.74M 34.81M
Reconciled depreciation - 0.61M 0.51M 0.60M 0.41M
Ebit 14.66M 12.85M 12.59M 10.77M 11.31M
Ebitda 15.66M 13.46M 13.10M 11.37M 11.71M
Depreciation and amortization 1.01M 0.61M 0.51M 0.60M 0.41M
Non operating income net other - - - - -
Operating income 14.66M 11.66M 12.21M 10.77M 11.31M
Other operating expenses 78.61M 67.62M 61.95M 56.17M 46.09M
Interest expense 0.35M 0.21M 0.14M 0.03M 0.10M
Tax provision 4.00M 3.86M 3.37M 3.40M 2.95M
Interest income 0.88M 1.04M 0.56M 0.13M 0.08M
Net interest income - 0.83M 0.42M 0.10M 0.04M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 4.00M 3.86M 3.37M 3.40M 2.95M
Total revenue 93.27M 79.50M 74.16M 66.89M 57.10M
Total operating expenses 41.37M 35.59M 30.39M 29.02M 23.80M
Cost of revenue 37.24M 32.26M 31.56M 27.15M 22.29M
Total other income expense net -0.22700M 0.59M 0.24M -0.03400M -0.10500M
Discontinued operations - - - - -
Net income from continuing ops - 8.78M 9.08M 7.34M 8.25M
Net income applicable to common shares 10.44M 8.78M 9.08M 7.08M 8.29M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 82.36M 71.88M 59.81M 51.80M 45.27M
Intangible assets - 0.05M - 0.01000M 0.00000M
Earning assets - - - - -
Other current assets 1.56M 1.99M 1.29M 0.47M 0.31M
Total liab 26.20M 19.61M 16.48M 15.30M 14.85M
Total stockholder equity 56.25M 52.35M 43.40M 36.57M 30.75M
Deferred long term liab - - - - -
Other current liab 11.25M 13.39M 6.33M 10.06M 3.52M
Common stock 42.79M 45.03M 42.57M 41.90M 41.63M
Capital stock - 45.03M - 41.90M 41.63M
Retained earnings 5.20M 0.85M -2.76900M -8.48200M -12.52800M
Other liab - - - 0.14M 0.20M
Good will - - - - -
Other assets - - - 2.16M 1.90M
Cash 35.56M 28.60M 24.63M 15.69M 15.89M
Cash and equivalents - - - - -
Total current liabilities 24.16M 19.27M 16.22M 14.86M 14.46M
Current deferred revenue 5.70M - 4.09M - 6.94M
Net debt -31.26000M -28.08400M -24.24300M -15.08700M -15.52000M
Short term debt 0.48M 0.30M 0.21M 0.30M 0.19M
Short long term debt - - - - -
Short long term debt total 4.30M 0.52M 0.39M 0.60M 0.37M
Other stockholder equity 0.86M 0.00000M 0.86M 0.20M 1.65M
Property plant equipment - - - 8.47M 8.26M
Total current assets 65.84M 58.90M 48.29M 41.16M 35.10M
Long term investments - - - - -
Net tangible assets - - - - 30.75M
Short term investments - - - 3.85M 5.99M
Net receivables 13.64M 11.71M 11.21M 8.98M 7.12M
Long term debt - - - - 0.00000M
Inventory 15.08M 16.60M 11.15M 15.41M 11.31M
Accounts payable 6.73M 5.58M 5.58M 4.50M 3.82M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 7.40M 6.48M 2.74M 3.15M 1.65M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 2.66M 0.03M - -
Deferred long term asset charges - - - - -
Non current assets total 16.52M 12.99M 11.52M 10.64M 10.17M
Capital lease obligations - 0.52M - 0.60M 0.37M
Long term debt total - - - 0.30M 0.18M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.19800M -0.66000M -0.13900M -0.15500M
Change to liabilities - - - 0.52M 1.26M
Total cashflows from investing activities -0.57000M -0.19800M -0.66000M -0.13900M -0.15500M
Net borrowings - - - -0.33800M -1.53400M
Total cash from financing activities -9.08500M -2.99200M -2.87500M -3.10500M -4.38900M
Change to operating activities - - - 0.08M 0.04M
Net income 10.44M 8.78M 9.08M 7.08M 8.29M
Change in cash 6.96M 3.97M 8.94M -0.20500M 1.42M
Begin period cash flow 28.60M 24.63M 15.69M 15.89M 14.48M
End period cash flow 35.56M 28.60M 24.63M 15.69M 15.89M
Total cash from operating activities 16.43M 6.16M 12.98M 7.68M 5.89M
Issuance of capital stock - 3.86M 0.87M 0.58M 0.04M
Depreciation 1.01M 0.61M 0.51M 0.60M 0.41M
Other cashflows from investing activities - - - - -
Dividends paid 6.08M -5.16900M -3.36700M 3.04M 2.90M
Change to inventory 1.52M -5.44600M 4.26M -4.10000M -4.18300M
Change to account receivables -1.64200M -0.78200M -2.23800M -1.86000M -0.17500M
Sale purchase of stock -2.23700M -1.39300M -0.20800M -0.31100M 0.04M
Other cashflows from financing activities -0.76900M 3.86M -0.17100M -0.13900M -0.15500M
Change to netincome - - - 1.39M 0.18M
Capital expenditures 0.57M 0.20M 0.66M 0.14M 0.15M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 4.78M -6.20400M 2.38M 0.13M 0.14M
Stock based compensation - 0.43M 0.68M - -
Other non cash items 0.20M 2.53M -0.97300M -7.68300M -8.70100M
Free cash flow 15.86M 5.96M 12.32M 7.54M 5.73M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
VLS
Vita Life Sciences Ltd		 -0.02 0.80% 2.48 13.89 42.73 1.46 2.42 1.24 6.53
AFP
Aft Pharmaceuticals Ltd		 - -% 3.00 23.08 19.88 1.35 3.81 1.72 13.67
SNT
Syntara Ltd		 -0.001 3.33% 0.03 - 20.45 6.32 4.62 6.32 -2.1607
MVP
Medical Developments International Ltd		 0.005 1.23% 0.41 - 166.67 1.14 0.83 0.75 11.48
LGP
Little Green Pharma Ltd		 -0.01 8.70% 0.10 5.25 43.29 0.83 0.41 0.98 19.49

Reports Covered

Stock Research & News

View All

Profile

Vita Life Sciences Limited, a healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. The company offers various minerals, herbs, and superfoods. It markets its products through pharmacies and health food channels under the Herbs of Gold, VitaHealth, and VitaScience brands. The company was founded in 1947 and is headquartered in Mascot, Australia.

Vita Life Sciences Ltd

Suite 802, Level 8, Mascot, NSW, Australia, 2020

Key Executives

Name Title Year Born
Mr. Andrew W. O'Keefe MD & Director NA
Mr. Chin Leng Khoo AGIA, C.A., C.P.A., M.B.A. CFO, Company Sec. & Acting CEO of Asia Region NA
Ms. Melissa Pereira Head of Marketing NA
Mr. Shaun Rutherford Head of Sales NA
Ms. K. S. Beh Country Head of Vita Life Sciences Malaysia & Singapore NA
Ms. June Lau Gen. Mang. of Operations & Bus. Support NA
Alexandra Ward Technical & NPD Mang. NA
Mr. Chin Leng Khoo AGIA, C.A., C.P.A., M.B.A. CFO, Company Secretary & Acting CEO of Asia Region NA
Ms. Melissa Pereira Group Marketing Manager (Leave of Absence) NA
Mr. Shaun Rutherford Chief Executive Officer of Herbs of Gold ANZ NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.